These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33860447)

  • 1. Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases.
    Deng Z; Liu S
    Drug Deliv Transl Res; 2021 Aug; 11(4):1475-1497. PubMed ID: 33860447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy.
    Long J; Liang X; Ao Z; Tang X; Li C; Yan K; Yu X; Wan Y; Li Y; Li C; Zhou M
    Acta Biomater; 2024 Oct; 188():27-47. PubMed ID: 39265673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioresponsive drug delivery systems for the treatment of inflammatory diseases.
    Dou Y; Li C; Li L; Guo J; Zhang J
    J Control Release; 2020 Nov; 327():641-666. PubMed ID: 32911014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
    Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
    Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Nanotechnologies and Microbiome Engineering for the Treatment of Inflammatory Bowel Disease.
    Abed OA; Attlassy Y; Xu J; Han K; Moon JJ
    Mol Pharm; 2022 Dec; 19(12):4393-4410. PubMed ID: 35878420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drug delivery systems with traditional routes - A roadmap to chronic inflammatory diseases.
    Min K; Sahu A; Jeon SH; Tae G
    Adv Drug Deliv Rev; 2023 Dec; 203():115119. PubMed ID: 37898338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wielding the double-edged sword: Redox drug delivery systems for inflammatory bowel disease.
    Chen Y; Shui M; Yuan Q; Vong CT; Yang Z; Chen Z; Wang S
    J Control Release; 2023 Jun; 358():510-540. PubMed ID: 37169178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hierarchical structured and programmed vehicles deliver drugs locally to inflamed sites of intestine.
    Li W; Li Y; Liu Z; Kerdsakundee N; Zhang M; Zhang F; Liu X; Bauleth-Ramos T; Lian W; Mäkilä E; Kemell M; Ding Y; Sarmento B; Wiwattanapatapee R; Salonen J; Zhang H; Hirvonen JT; Liu D; Deng X; Santos HA
    Biomaterials; 2018 Dec; 185():322-332. PubMed ID: 30267958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug targeting systems for inflammatory disease: one for all, all for one.
    Crielaard BJ; Lammers T; Schiffelers RM; Storm G
    J Control Release; 2012 Jul; 161(2):225-34. PubMed ID: 22226771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems.
    Hadji H; Bouchemal K
    Adv Drug Deliv Rev; 2022 Feb; 181():114101. PubMed ID: 34999122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.
    Guo Y; Zong S; Pu Y; Xu B; Zhang T; Wang B
    Molecules; 2018 Jul; 23(7):. PubMed ID: 29973488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
    Li S; Xie A; Li H; Zou X; Zhang Q
    J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trehalosomes: Colon targeting trehalose-based green nanocarriers for the maintenance of remission in inflammatory bowel diseases.
    Abd-Elsalam WH; Saber MM; Abouelatta SM
    Eur J Pharm Biopharm; 2021 Sep; 166():182-193. PubMed ID: 34171496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges.
    Nunes R; Neves JD; Sarmento B
    Nanomedicine (Lond); 2019 Oct; 14(19):2631-2644. PubMed ID: 31612773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease.
    Qiao H; Fang D; Chen J; Sun Y; Kang C; Di L; Li J; Chen Z; Chen J; Gao Y
    Drug Deliv; 2017 Nov; 24(1):233-242. PubMed ID: 28156160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of benzoylaconitine using biodegradable nanoparticles to suppress inflammation via regulating NF-κB signaling.
    Gai W; Hao X; Zhao J; Wang L; Liu J; Jiang H; Jin H; Liu G; Feng Y
    Colloids Surf B Biointerfaces; 2020 Jul; 191():110980. PubMed ID: 32252000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smart Responsive Quercetin-Conjugated Glycol Chitosan Prodrug Micelles for Treatment of Inflammatory Bowel Diseases.
    Shen C; Zhao L; Du X; Tian J; Yuan Y; Jia M; He Y; Zeng R; Qiao R; Li C
    Mol Pharm; 2021 Mar; 18(3):1419-1430. PubMed ID: 33522827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.